Azitra (AZTR) News Today $1.07 +0.09 (+9.18%) Closing price 04:10 PM EasternExtended Trading$0.99 -0.08 (-7.57%) As of 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisChartEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestBuy This Stock AZTR Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 Time Period Azitra Inc Modifies Agreement with Alumni Capital5 hours ago | tipranks.comWhy Is Azitra (AZTR) Stock Soaring TodayAugust 28 at 9:48 AM | uk.finance.yahoo.comAzitra doses first patient in Phase 1/2 clinical trial of ATR04-484August 28 at 9:48 AM | msn.comWhat is Zacks Small Cap's Forecast for Azitra Q3 Earnings?August 28 at 2:23 AM | americanbankingnews.comAzitra shares surge after first patient receives ATR04-484 in Phase 1/2 trialAugust 27 at 3:14 PM | msn.comAzitra stock soars after first patient dosed in Phase 1/2 trialAugust 27 at 10:13 AM | za.investing.comAzitra, Inc. Announces First Patient Dosed in Phase 1/2 Trial for ATR-04 Program Targeting Oncology Patients with EGFRi-Associated RashAugust 27 at 8:10 AM | prnewswire.comAZTR: Second Quarter UpdateAugust 25, 2025 | finance.yahoo.comStock Market Today: Nasdaq, Dow, S&P 500 Futures Rise Ahead Of Powell's Speech At Jackson Hole—EpicQuest, Zoom, Azitra Stocks In FocusAugust 22, 2025 | benzinga.comAzitra, Inc. Announces Q2 2025 Results and Provides Business UpdatesAugust 11, 2025 | prnewswire.comAzitra, Inc. Announces Reverse Stock SplitAugust 11, 2025 | prnewswire.comAzitra Inc Approves Increase in Common Stock SharesJuly 3, 2025 | tipranks.comAzitra, Inc.: Azitra Reports Promising Safety Data from Phase 1b Trial in Netherton SyndromeJune 17, 2025 | finanznachrichten.deAzitra Reports Promising Safety Data from Phase 1b Trial in Netherton SyndromeJune 17, 2025 | prnewswire.comAzitra, Inc. Announces Presentation at the 2025 BIO International ConventionJune 10, 2025 | prnewswire.comAzitra, Inc. Announces Presentation at ASCO 2025 Highlighting Clinical Trial Investigating ATR-04 for EGFRi-Associated RashMay 28, 2025 | prnewswire.comAZTR: ATR-04 Trial to Dose 1st Patient Mid-2025May 21, 2025 | finance.yahoo.comAzitra, Inc. to Present Abstract at American Society of Gene and Cell Therapy Highlighting Phase 1/2 Study Targeting Cancer Therapy-Associated RashMay 14, 2025 | prnewswire.comAzitra, Inc. Announces Q1 2025 Results and Provides Business UpdatesMay 13, 2025 | prnewswire.comAzitra secures funding deal for dermatology treatmentsApril 26, 2025 | investing.comAzitra, Inc. to Present ATR-04 Program Update at ASCO 2025 | AZTR Stock NewsApril 25, 2025 | gurufocus.comAzitra, Inc. to Present ATR-04 Program Update at ASCO 2025April 25, 2025 | gurufocus.comAzitra enters share purchase agreement with Alumni Capital LPApril 25, 2025 | markets.businessinsider.comAzitra, Inc. to Present ATR-04 Program Update at ASCO 2025April 25, 2025 | prnewswire.comAzitra Announces Share Purchase Agreement for up to $20 Million in Partnership with Alumni Capital to Fund Clinical PipelineApril 24, 2025 | prnewswire.comAzitra to Present at Microbiome Times Partnering ForumMarch 12, 2025 | prnewswire.comAZTR: Netherton Topline Expected by Year-EndMarch 3, 2025 | msn.comMaxim Group Reaffirms Their Buy Rating on Azitra Inc (AZTR)February 27, 2025 | markets.businessinsider.comAzitra, Inc. Announces Full Year 2024 Financial Results and Provides Business UpdatesFebruary 24, 2025 | gurufocus.comAzitra, Inc. Announces Full Year 2024 Financial Results and Provides Business UpdatesFebruary 24, 2025 | prnewswire.comAzitra Inc. issues new warrants in connection with stock saleFebruary 7, 2025 | msn.comAzitra sees 3.34M shares at 27.85c in registered direct offeringFebruary 5, 2025 | markets.businessinsider.comAzitra secures $930K in registered direct offeringFebruary 5, 2025 | msn.comAzitra Announces Pricing of $930.0 Thousand Registered Direct Offering of Common StockFebruary 4, 2025 | prnewswire.comAzitra, Inc. to Present at the BIO CEO & Investor ConferenceFebruary 3, 2025 | prnewswire.comAzitra, Inc. to Present at The Microcap ConferenceJanuary 27, 2025 | prnewswire.comAzitra Announces Pricing of $1.5 Million Public Offering of Common StockJanuary 15, 2025 | prnewswire.comAzitra Announces Proposed Public Offering of Common StockJanuary 14, 2025 | prnewswire.comAZTR: Planning 2nd Site for ATR-12 TrialNovember 16, 2024 | finance.yahoo.comPromising Prospects for Azitra Inc: Buy Rating Supported by Advancements in ATR-12 and ATR-04 ProgramsNovember 15, 2024 | markets.businessinsider.comAzitra, Inc. Announces Q3 2024 Financial Results and Provides Business UpdatesNovember 12, 2024 | prnewswire.comAzitra, Inc.: Azitra to Present at BIO-Europe 2024October 30, 2024 | finanznachrichten.deAzitra to Participate in the 2024 Maxim Healthcare Virtual SummitOctober 11, 2024 | finance.yahoo.comStrong Buy Rating on Azitra Inc. for Promising Therapeutic Candidates in Oncology and Rare DiseasesSeptember 26, 2024 | markets.businessinsider.comAzitra, Inc. Announces Late-Breaking Presentation at the European Academy of Dermatology and Venereology CongressSeptember 24, 2024 | finance.yahoo.comBuy Rating Justified by Azitra Inc’s Advances in Rare Skin Disease Treatments and Financial StabilitySeptember 20, 2024 | markets.businessinsider.comAzitra Receives Fast Track Designation for ATR-04 for Skin Rash from EGFR InhibitorsSeptember 18, 2024 | finance.yahoo.comAzitra's ATR-04 Gets FDA Fast Track Designation For Skin Rash Linked To EGFR InhibitorsSeptember 18, 2024 | markets.businessinsider.comAzitra to Present at the H.C. Wainwright 26th Annual Global Investment ConferenceSeptember 7, 2024 | finance.yahoo.comAzitra Announces First Patient Dosed in Phase 1b Trial of ATR-12 for Netherton SyndromeAugust 28, 2024 | finance.yahoo.com Get Azitra News Delivered to You Automatically Sign up to receive the latest news and ratings for AZTR and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. AZTR Media Mentions By Week AZTR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. AZTR News Sentiment▼-0.201.03▲Average Medical News Sentiment AZTR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. AZTR Articles This Week▼121▲AZTR Articles Average Week Get the Latest News and Ratings for AZTR and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Azitra and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies IMCC News CTXR News CHHE News PRPH News MRKR News BFRG News ALVR News LGVN News IBIO News GELS News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSEAMERICAN:AZTR) was last updated on 8/29/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredThis is my Christian duty“This land I will give to you…” — a 4,000-year-old line from Genesis may hold the key to unlocking a $150 tril...Paradigm Press | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Azitra, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Azitra With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access